Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
Moodys
Colorcon
Merck

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENSTILAR

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Enstilar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02881346 Efficacy and Tolerability of Enstilar® in Daily Practice Recruiting LEO Pharma N/A 2016-10-01 This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,
NCT02935582 PSOREAL - Managing PSOriasis in the REAL World Not yet recruiting LEO Pharma N/A 2016-10-01 Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).
NCT03441789 Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis Recruiting Leon Kircik, M.D. Phase 4 2017-09-18 This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam.
NCT03506477 Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Recruiting Icahn School of Medicine at Mount Sinai Phase 4 2018-05-21 This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.
NCT03587194 Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis Recruiting Celgene Corporation Phase 4 2018-07-23 Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.
NCT03587194 Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis Recruiting Psoriasis Treatment Center of Central New Jersey Phase 4 2018-07-23 Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Enstilar

Condition Name

Condition Name for Enstilar
Intervention Trials
Plaque Psoriasis 4
Psoriasis 3
Psoriasis Vulgaris 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Enstilar
Intervention Trials
Psoriasis 8
Erythema Multiforme 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Enstilar

Trials by Country

Trials by Country for Enstilar
Location Trials
United States 23
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Enstilar
Location Trials
Kentucky 3
New York 2
South Carolina 2
California 2
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Enstilar

Clinical Trial Phase

Clinical Trial Phase for Enstilar
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Enstilar
Clinical Trial Phase Trials
Recruiting 6
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Enstilar

Sponsor Name

Sponsor Name for Enstilar
Sponsor Trials
LEO Pharma 3
Psoriasis Treatment Center of Central New Jersey 2
Derm Research, PLLC 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Enstilar
Sponsor Trials
Other 5
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Express Scripts
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.